Skip to main content
Accelerating Clinical Trials in the EU

Multi-stakeholder platform

MSP Advisory Group

The MSP Advisory Group (MSP AG) is composed of representatives from key stakeholders who provide:

  • strategic advice regarding the ACT EU workplan, identifying stakeholder priorities;
  • operational advice for ACT EU initiatives, identifying experts and engagement methodology.

The full composition is available on the page MSP AG members 

doc icon
General publications4 November 2024
MSP Advisory Group Mandate and rules of procedure

 

MSP Advisory Group meetings

For information on upcoming and past meetings of the MSP AG, including meeting materials, see below.

Meeting dates

Document icon
General publications3 June 2024
MSP Advisory group and MSP annual meeting dates 2024-2026

This document outlines the 2024-2026 meeting dates for the MSP Advisory group and the MSP annual meetings.

 

Events

News

MSP documents

Document icon
General publications5 April 2024
MSP Advisory Group Mandate and rules of procedure

This document outlines the MSP Advisory Group’s mandate and rules of procedures.

Document icon.
General publications21 September 2023
Kick-off meeting report - ACT EU multi-stakeholder platform

The summary report of the first ACT EU MSP workshop held in June 2023, to understand different stakeholder perspectives on how to transform the EU environment for clinical trials, discuss the feedback from the MSP public consultation and agree on a model for the establishment of the MSP.

doc_icon
General publications12 July 2023
Outcome of public consultation on ACT EU MSP participation and priorities for discussion

The report on the outcome of a public consultation where the European Medicines Agency invited stakeholders to provide input on the ACT EU MSP concept paper, priority topics for the MSP and to express their interest in participating.

doc_icon
General publications13 October 2023
ACT EU multi-stakeholder platform concept paper

A concept paper is available on the importance of engaging stakeholders in all phases of a clinical trial, including trial design, and the objectives, composition, governance and transparency rules for the multi-stakeholder platform.